THRAP3 and metabolic dysfunction-associated steatotic liver disease: Taken together, these results suggest that Thrap3 inhibits AMPK activity by regulating AMPK translocation through its C-terminus, which further inhibits AMPK-mediated autophagy and mitochondrial quality control and consequently exacerbates NAFLD.